Literature DB >> 15271891

Chlamydia trachomatis-specific human CD8+ T cells show two patterns of antigen recognition.

Malgosia K Matyszak1, J S Hill Gaston.   

Abstract

Chlamydia trachomatis is an intracellular gram-negative bacteria which causes several clinically important diseases. T-cell-mediated immunity and the production of gamma interferon (IFN-gamma) are known to be essential for the clearance of the bacteria in vivo. Here we have investigated CD8(+)-T-cell responses to C. trachomatis in patients with previous episodes of chlamydia infection. To isolate C. trachomatis-specific CD8(+)-T-cell lines, dendritic cells (DC) were infected with C. trachomatis and cocultured with purified CD8(+) T cells to generate C. trachomatis-specific CD8(+)-T-cell lines which were then cloned. Two patterns of recognition of C. trachomatis-infected cells by CD8(+)-T-cell clones were identified. In the first, C. trachomatis antigens were recognized in association with classical class I HLA antigens, and responses were inhibited by class I HLA-specific monoclonal antibodies. The second set of clones was unrestricted by classical HLA class I, and further studies showed that CD1 molecules were also not the restriction element for those clones. Both types of clones produced IFN-gamma in response to C. trachomatis and were able to lyse C. trachomatis-infected target cells. However, unrestricted clones recognized C. trachomatis-infected cells at much earlier time points postinfection than HLA-restricted clones. Coculture of C. trachomatis-infected DC with the C. trachomatis-specific clones induced DC activation and a rapid enhancement of interleukin-12 (IL-12) production. Early production of IL-12 during C. trachomatis infection, facilitated by unrestricted CD8(+)-T-cell clones, may be important in ensuring a subsequent Th1 T-cell-mediated response by classical major histocompatibility complex-restricted CD4(+) and CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271891      PMCID: PMC470615          DOI: 10.1128/IAI.72.8.4357-4367.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Identification and characterization of a DR4-restricted T cell epitope within chlamydia heat shock protein 60.

Authors:  K H Deane; R M Jecock; J H Pearce; J S Gaston
Journal:  Clin Exp Immunol       Date:  1997-09       Impact factor: 4.330

2.  Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism.

Authors:  S J Mehta; R D Miller; J A Ramirez; J T Summersgill
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

3.  Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4(+) T cells from humans infected with Chlamydia trachomatis.

Authors:  J C Goodall; H Beacock-Sharp; K H Deane; J S Gaston
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice.

Authors:  T W Cotter; K H Ramsey; G S Miranpuri; C E Poulsen; G I Byrne
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice.

Authors:  W Kuon; R Lauster; U Böttcher; A Koroknay; M Ulbrecht; M Hartmann; M Grolms; S Ugrinovic; J Braun; E H Weiss; J Sieper
Journal:  Arthritis Rheum       Date:  1997-05

6.  Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers.

Authors:  S K Kim; L Devine; M Angevine; R DeMars; P B Kavathas
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans?

Authors:  M Johansson; K Schön; M Ward; N Lycke
Journal:  Scand J Immunol       Date:  1997-12       Impact factor: 3.487

8.  Clearance of Chlamydia trachomatis-induced polyserositis in SCID mice requires both CD4+ and CD8+ cells.

Authors:  S Thoma-Uszynski; U Simnacher; R Marre; A Essig
Journal:  Med Microbiol Immunol       Date:  1998-10       Impact factor: 3.402

9.  Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection.

Authors:  M F Lampe; C B Wilson; M J Bevan; M N Starnbach
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation.

Authors:  T Fan; H Lu; H Hu; L Shi; G A McClarty; D M Nance; A H Greenberg; G Zhong
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more
  4 in total

1.  Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers.

Authors:  Muneer Abbas; Linda D Bobo; Yu-Hsiang Hsieh; Noureddine Berka; Georgia Dunston; George E Bonney; Victor Apprey; Thomas C Quinn; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

2.  An atypical CD8 T-cell response to Chlamydia muridarum genital tract infections includes T cells that produce interleukin-13.

Authors:  Raymond M Johnson; Micah S Kerr; James E Slaven
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

3.  A Class II-Restricted CD8γ13 T-Cell Clone Protects During Chlamydia muridarum Genital Tract Infection.

Authors:  Raymond M Johnson; Norma Olivares-Strank; Gang Peng
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

4.  The frequency of Chlamydia trachomatis major outer membrane protein-specific CD8+ T lymphocytes in active trachoma is associated with current ocular infection.

Authors:  Martin J Holland; Nkoyo Faal; Isatou Sarr; Hassan Joof; Mass Laye; Ewen Cameron; Frederick Pemberton-Pigott; Hazel M Dockrell; Robin L Bailey; David C W Mabey
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.